Fragile X Syndrome Treatment Target: MMP-9

A major article from the Ethell lab at UC Riverside has shown the therapeutic potential of drugs that inhibit the enzyme MMP-9. A nice lay description of the new paper is here and the abstract of the article is here.  Dr. Ethell was awarded FRAXA Research Foundation funding from 2008-2011 and 2012-present.

This latest work shows that human Fragile X tissues have elevated levels of the extracellular enzyme MMP-9, as well as an increase in the active fraction of that protein (like most enzymes, MMP-9 can exist in an inactive form which can be switched on rapidly; this kind of regulation is important in most biological pathways.)

The Ethell lab also showed that genetic reduction of MMP-9 rescues most Fragile X phenotypes in the mouse model. Previous work had shown that inhibition of MMP-9 with minocycline also had similar effects, but minocycline has many different actions. These experiments demonstrate conclusively that MMP-9 inhibition is the active ingredient. This is important, because pharma companies are working on drugs which inhibit MMP-9 without the antibiotic effects.

Iryna Ethell UC Riverside, FRAXA researcher

Iryna Ethell is a professor at UC Riverside and a FRAXA-funded researcher. Credit: L. Duka.

They also showed that inhibition of this extracellular enzyme can normalize the activity of many of the intracellular signaling pathways (i.e. mTOR) that have been the focus of much recent Fragile X research. And, perhaps most interesting of all, they showed that genetic reduction of MMP-9 rescues the macro-orchidism phenotype in Fragile X, something which has been relatively resistant to rescue with other therapeutic strategies. Since MMP-9 is a gelatinase, we have previously hypothesized that excessive MMP-9 activity in Fragile X was responsible for the well-described lax connective tissue; confirmation that MMP-9 activity is indeed elevated in human Fragile X tissue lends support for this idea, though this phenotype is difficult to measure in mice, so rescue effects were not assessed in this study.

All in all, this latest article adds to the growing body of evidence that MMP-9 dysregulation is a critical part of the pathology of Fragile X, and MMP-9 should be considered a major treatment target for Fragile X.

THE AUTHOR

Dr. Tranfaglia is Medical Director and Chief Scientific Officer of FRAXA Research Foundation, coordinating the Foundation’s research strategy and working with university and industry scientists to develop new therapeutic agents for Fragile X. He has a BA in Biology from Harvard University and an MD from the University of North Carolina at Chapel Hill. His son Andy has Fragile X syndrome.

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.